Randomized trial · people
Efinopegdutide: up to 7.2% more weight loss than placebo at 12 weeks
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In people with type 2 diabetes and severe obesity, efinopegdutide lowered weight in a dose-linked way over 12 weeks, but it did not improve blood sugar control and caused more nausea and vomiting than placebo.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 195
- Published
- 2021
- Journal
- Clin Obes
What they tested
This phase 2 study compared three doses of efinopegdutide with placebo to see how much weight people with type 2 diabetes and class II/III obesity lost over 12 weeks, and how safe the drug was.
How the study was done
A phase 2, randomized, double-blind, placebo-controlled trial in 195 dosed people with type 2 diabetes (HbA1c, a long-term average of blood sugar, of 6.5%-9.5%) and a body mass index of 35 to 50 kg/m2. They were split evenly into placebo (a dummy treatment) or a 5.0 mg, 7.4 mg or 10.0 mg arm, and the main measure was percent change in body weight at week 12.

Model. Individual results vary.
What they found
After removing the placebo effect, body weight fell by 4.6% in the 5.0 mg arm, 5.9% in the 7.4 mg arm and 7.2% in the 10.0 mg arm at week 12, with bigger doses giving more weight loss. HbA1c did not change at any dose, fasting insulin rose slightly, and fasting blood sugar went up in the 5.0 mg and 7.4 mg arms. Side effects, mainly nausea and vomiting, were more common than on placebo, and 144 of 195 people (73.8%) finished treatment.
What it doesn’t show
This was a short 12-week dose-finding trial, so it does not show whether the weight loss lasts or what happens over longer use. About a quarter of participants did not complete treatment.
The paper
Di Prospero et al. Efficacy and safety of glucagon-like peptide-1/glucagon receptor co-agonist JNJ-64565111 in individuals with type 2 diabetes mellitus and obesity: A randomized dose-ranging study. Clin Obes. 2021.
The compound
More studies on Efinopegdutide
- Efinopegdutide: MASH resolved in up to 63% vs 13% on placeboRandomized trial · people · 2026
- Efinopegdutide: 72.7% liver fat drop vs 42.3% on semaglutideRandomized trial · people · 2023
- Every study on Efinopegdutide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.